6月10日 - ** 药物开发商 Unicycive Therapeutics UNCY.O 股价盘前下跌 27% 至 65 美分
** UNCY 称美国 FDA 发现其肾病药物碳酸氧杂环庚烷的第三方供应商存在生产问题 (link)
** 该公司称，在这些问题得到解决之前，FDA 不能与 UNCY 讨论药物标签问题
** 补充说，该公司正在努力解决 FDA 提出的问题，并对该药物治疗高磷酸盐血症的潜力充满信心。
** 尽管存在问题，FDA 仍有望在 6 月 28 日原定行动日期前做出最终决定
** 截至上次收盘，股价累计上涨 13.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.